查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424443

全球艾伦赫恩登达德利症候群治疗市场：依治疗类型、最终用户、地区

Global Allan-Herndon-Dudley Syndrome Treatment Market, By Treatment Type (Gene Therapy, Hormone Therapy), By End User (Hospital, Specialty Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
出版日期: | 出版商: Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球艾伦赫恩登达德利症候群 (AHDS)（MCT8 缺乏症）市场规模预计将从 2023 年的 1,200 万美元增至 2030 年的 1,750 万美元，预测期内的年复合成长率(CAGR)为5.5%。

报告范围 报告详情
基准年 2022年 2023/2024年市场规模 1200万美元
实际资料 2018-2021 预测期 2023-2030
预测期间 2023/2024 至 2030/2031 年复合年增长率： 5.50% 2030/2031价值预测 1750万美元
图 1. 2023 年艾伦赫恩登-达德利症候群 (AHDS)（MCT8 缺陷）治疗的全球市场占有率（%），按地区划分
全球艾伦-赫恩登-达德利症候群治疗市场-IMG1

艾伦·赫恩登·达德利症候群 (AHDS) 是一种由 MCT8 基因突变引起的罕见遗传疾病。这些突变导致甲状腺激素穿过血脑障壁的运输受损。目前 AHDS 的治疗选择有限，且旨在控制症状。第一线治疗是使用三碘甲状腺原氨酸 (T3) 进行甲状腺荷尔蒙补充疗法。 T3补充品可以帮助恢復大脑中的甲状腺激素水平并改善神经发育和功能。然而，高剂量的T3有时会引起副作用，如震颤、过动症和心律不整。另一种选择是甲状腺素 (T4) 疗法，它依赖 T4 在细胞内外周转化为活性 T3。这种间接治疗方法效果较差，因为 MCT8 突变会抑制荷尔蒙转运和活化。

新兴的基因疗法是一种有前景的研究方法，可以直接治疗 AHDS 的潜在遗传原因。基因治疗涉及将 MCT8 基因的正常副本引入患者的细胞或组织中以替换突变基因。儘管仍处于研究的早期阶段，但这可以纠正激素运输缺陷并消除终身甲状腺替代方案的需要。挑战包括开发有效且安全的基因转移载体，以及根据特定的 MCT8 突变为个别患者量身定制治疗方案。进一步的研究正在进行中，以检验基因疗法作为未来 AHDS 的创新治疗方法。

市场动态：

全球艾伦赫恩登达德利症候群 (AHDS)（MCT8 缺陷）治疗市场主要是由 AHDS 盛行率不断上升推动的，预计这将在预测期内推动市场成长。例如，根据美国国家生物技术资讯中心（NCBI）2020年1月16日发布的资料，在大约15年的时间里，已有超过160人被确认受到影响，这意味着这种症候群比之前想像的更为普遍。也被建议为常见的。

研究的主要特点

  • 本报告对全球Allan Herndon-Dudley症候群（AHDS）（MCT8缺陷）治疗药物市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率.（复合年增长率%）。
  • 它还强调了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球艾伦赫恩登-达德利症候群 (AHDS)（MCT8 缺乏症）治疗市场的主要企业进行了分析。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
  • 全球艾伦赫恩登-达德利症候群 (AHDS) (MCT8 缺乏症) 治疗市场报告针对该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进入者和财务分析师。
  • 相关人员可以透过用于分析全球艾伦赫恩登-达德利症候群 (AHDS)（MCT8 缺乏症）治疗市场的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • AHDS 盛行率增加
    • 全球医疗保健支出增加
  • 主要亮点
  • 监管场景
  • 最近的趋势
  • PEST分析
  • 波特的分析
  • 合併、收购和合作

第四章全球艾伦赫恩登达德利症候群 (AHDS)（MCT8 缺乏症）治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第 5 章全球艾伦赫恩登-达德利症候群 (AHDS)（MCT8 缺乏症）治疗市场，依治疗类型，2018-2030 年

  • 基因治疗
  • 荷尔蒙疗法

第 6 章 全球艾伦赫恩登-达德利症候群 (AHDS)（MCT8 缺乏症）治疗市场，按最终用户划分，2018-2030 年

  • 医院
  • 专科诊所
  • 其他（调查机构等）

第7章全球艾伦赫恩登达德利症候群（AHDS）（MCT8缺乏症）治疗市场，按地区，2018-2030年

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第八章 竞争形势

  • 公司简介
    • Rare Thyroid Therapeutics International AB
    • Erasmus Medical Center

第9章 章节

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6559

The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) market size is expected to reach US$ 17.5 Mn by 2030, from US$ 12 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 12 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 5.50% 2030/2031 Value Projection: US$ 17.5 Mn
Figure 1. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market Share (%), By Region, 2023
Global Allan-Herndon-Dudley Syndrome Treatment Market - IMG1

Allan-Herndon-Dudley syndrome (AHDS) is a rare genetic disorder caused by mutations in the MCT8 gene. These mutations result in impaired thyroid hormone transport across the blood-brain barrier. Current treatment options for AHDS are limited and aim to manage symptoms. The first line of treatment involves thyroid hormone replacement therapy with triiodothyronine (T3). T3 supplements help restore thyroid hormone levels in the brain to improve neurological development and function. However, high T3 doses sometimes cause side effects like tremors, hyperactivity, and irregular heartbeat. The other option is thyroxine (T4) therapy which relies on the peripheral conversion of T4 to active T3 within cells. This indirect method of treatment is not very effective as the MCT8 mutations disrupt hormone transportation and activation.

Emerging gene therapy is a promising investigational approach to directly treat the underlying genetic cause of AHDS. In gene therapy, a normal copy of the MCT8 gene would be delivered into the patient's cells and tissues to replace the mutated one. Though still in early research phase, this could correct the hormone transport defect and eliminate the need for lifelong thyroid supplementation. Challenges include developing effective and safe gene delivery vectors and treatments needing to be tailored to individual patients based on their specific MCT8 mutations. More research is underway to validate gene therapy as an innovative treatment for AHDS in the future.

Market Dynamics:

The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market is mainly driven by the increasing prevalence of AHDS is expected to propel the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information (NCBI) in January 16, 2020, the identification of more than 160 affected individuals in approximately 15 years suggests that the syndrome is more common than previously thought.

Key features of the study:

  • This report provides an in-depth analysis of the global allan-herndon-dudley syndrome (AHDS) (MCT8 deficiency) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Rare Thyroid Therapeutics International AB and Erasmus Medical Center
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) treatment market

Detailed Segmentation:

  • Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type
    • Gene Therapy
    • Hormone Therapy
  • Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User
    • Hospital
    • Specialty Clinics
    • Others (Research institutes, etc.)
  • Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • Latin America
  • Top Companies in the Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market:
    • Rare Thyroid Therapeutics International AB
    • Erasmus Medical Center

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment Type
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing prevalence of AHDS
    • Increasing Healthcare Expenditure Globally
  • Key Highlights
  • Regulatory Scenario
  • Recent Trends
  • PEST Analysis
  • PORTER's Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Treatment Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By End User, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Others (Research institutes, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 - 2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2018-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Company Profile
    • Rare Thyroid Therapeutics International AB
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Erasmus Medical Center
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us